focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,783.50
Bid: 1,780.00
Ask: 1,780.50
Change: -29.00 (-1.60%)
Spread: 0.50 (0.028%)
Open: 1,792.50
High: 1,802.00
Low: 1,775.50
Prev. Close: 1,812.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Strong End To Choppy Session On Tight US Poll

Wed, 04th Nov 2020 17:06

(Alliance News) - Stocks in London surged to a strong finish Wednesday as a tight US presidential election started to open up for Democratic challenger Joe Biden.

The FTSE 100 index got off to a sluggish start, but was able to close the session up 96.49 points, or 1.7% at 5,883.26 Wednesday. The blue-chip index had fallen by 1.0% to a low of 5,731.07 during a frenetic open.

The mid-cap FTSE 250 added 304.38 points, or 1.7%, at 17,796.08. The AIM All-Share closed up 15.36 points, 1.6%, at 974.74.

The Cboe UK 100 index closed up 1.7% at 584.13. The Cboe 250 ended up 1.5% at 14,961.24. The Cboe Small Companies grew 1.3% at 9,623.16.

The CAC 40 stock index in Paris advanced 2.4%, and Frankfurt's DAX 30 climbed 2.0%.

"It appears that once again investors are buying into a Joe Biden presidency, despite the race - which could still have days left in it yet - being on a knife-edge," SpreadEx analyst Connor Campbell said.

He continued: "Investors seem to be taking a kind of win-win attitude to the election. Yesterday's growth was based on the hopes of a blue wave led stimulus package. Now that the race is much tighter, and the Democrats have little chance of taking the Senate, the markets are celebrating the likelihood of preserved tax cuts and no healthcare reform."

President Donald Trump prematurely declared victory and sought Supreme Court intervention to stop vote-counting - even as his Democratic rival Joe Biden voiced confidence in his own chances.

Shattering norms in the world's most powerful democracy, Trump alleged "major fraud" as he held an upbeat rally inside the White House's ceremonial East Room.

Attention was again turning to three northern states that elected Trump four years ago - Michigan, Pennsylvania and Wisconsin - with early ballots still waiting to be counted from the Democratic stronghold cities of Detroit, Philadelphia and Milwaukee.

Pennsylvania Governor Tom Wolf said the state may not know its full election results on Wednesday. Wolf, a Democrat, urged patience, and said Pennsylvania intends to keep "the promise of democracy" that every vote counts.

Stocks in New York were in firmly green at the London equities close, with the Dow Jones Industrial Average up 2.4%, the S&P 500 index up 3.0%, and the Nasdaq Composite up 4.0%.

Oanda's Edward Moya said: "The Senate will likely stay red (that could change, but it is leaning heavily that way) and the Democrats House majority lead will shrink which means we won't see tax hikes, tougher regulation, and massive stimulus spending. The Nasdaq will outperform, and the great cyclical rotation won't happen anytime soon. Regardless of what happens with the presidential race over the next few days, financial markets are pricing a much more accommodative Fed and that should be bullish for US stocks."

In London, pharma firms were enjoying the potential split vote in the US, avoiding any regulations a Democratic-dominated Washington may have imposed.

AstraZeneca gained 6.6%, Hikma 2.5% and GlaxoSmithKline 4.4%.

IG senior market analyst Joshua Mahony added: "Astrazeneca has enjoyed a welcome boost in the wake of the news that the UK government could end up rolling out their vaccine as early as December. With Pfizer and Astrazeneca trials leading the way, much has been staked on the ability to find a suitable vaccine of from one of those two trials.

"For the short-term everyone has been caught up in election and lockdown fears, yet the ability to bring a vaccine to market out of these two front-runners will be critical in ensuring that we begin to see the end of this crisis."

Marks & Spencer added 5.1%. The retailer's interim performance was better than expected, despite swinging to a pretax loss of GBP87.6 million from a GBP158.8 million profit.

Revenue for the six months to September declined 16% to GBP4.09 billion from GBP4.86 billion a year before.

"Despite the company's historic loss, there are some encouraging signs in Marks & Spencer's update. The initial success of the Ocado partnership is highly promising and appears to be unlocking the food business's previously untapped online potential," said Brewin Dolphin Senior Investment Manager John Moore.

Ocado shares closed 5.3% higher.

Smurfit Kappa added 3.9%. The paper firm said its third-quarter performance was ahead of its expectations, with revenue year-to-date not far behind the prior year.

Dublin-based Smurfit reported revenue of EUR6.61 billion for the nine months ended September 30, down 3.5% from EUR6.85 billion the year before.

Smurfit also reported earnings before interest, tax, depreciation and amortisation of EUR1.13 billion, a 10% drop from EUR1.26 billion for the same period of 2019 but flat versus 2018's Ebitda figure.

Amid the chaos of the US election, blue-chip banks were bearing the brunt of the move into more defensive stocks, which is in stark contrast to the gains financials made on Tuesday prior to the polls closing in the US.

Standard Chartered lost 4.7% Wednesday, HSBC 4.2%, Barclays 2.6%, Lloyds 2.5% and NatWest 2.2%.

Defensive stocks, in contrast, fared bettered. Diageo added 3.6%, British American Tobacco 3.5% and BAE Systems 2.8%.

Turning to forex, the dollar had a strong start to the European session on Wednesday though its gains waned throughout the day.

The pound was quoted at USD1.2977 on Wednesday evening, down from USD1.3070 at the London equities close on Tuesday. However, sterling was as low as USD1.2915 earlier in trading.

The euro slipped to USD1.1710, from USD1.1729 late Tuesday.

Versus the yen, the dollar fetched JPY104.49, broadly flat from JPY104.50 at the London market close on Tuesday.

A barrel of the North Sea benchmark fetched USD40.62 Wednesday, up from USD39.64 a barrel at the London market close Tuesday.

Gold was quoted at USD1,901.50, down from USD1,906.10.

It's a big day in the international economic calendar Thursday, with interest rate decisions due from the Bank of England, at 0700 GMT, and the US Federal Reserve, at 1900 GMT.

Bank of America expects rising Covid-19 cases and restrictions, both in the UK and abroad, to cut the BoE's growth forecast for the UK economy by 40 basis points for 2020 and 140 basis points for 2021. The BoE now will likely model a GDP slide of 9.9% in 2020 and a rebound of 7.7% in 2021.

"In short we expect the BoE to continue moving from a 'V' to 'U'. Weaker growth should mean lower inflation at the policy relevant two-year horizon," Bank of America said, referring to the shape graph charting economic recovery.

Analysts are near unanimous in expecting the BoE to top up QE by a further GBP100 billion on Thursday in response to the darkening backdrop, after bumping up the programme by GBP100 billion in June to take the total stock of asset purchases to GBP745 billion.

Though it is all but certain the BoE will ease monetary policy this week, analysts don't think the bank will go as far as cutting interest rates into negative territory.

Elsewhere, there is a Jibun Bank services PMI print overnight, with Germany factory orders at 0600 GMT, and UK Markit construction PMI at 0930 GMT. Eurozone retail sales are due at 1000 GMT and the weekly US initial jobless claims are out at 1330 GMT.

In the UK corporate calendar, pharma giant AstraZeneca will issue third quarter results, blue chip grocer Sainsbury's, budget airline Wizz Air and Auto Trader will publish half-year results. Insurers RSA and Lancashire will release third quarter results.

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more
1 Feb 2024 09:27

TOP NEWS: GSK maintains "vigorous" defence after settling Zantac case

(Alliance News) - GSK PLC on Thursday insisted upon its scientific integrity, after reaching another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
1 Feb 2024 09:11

GSK settles Zantac case in California without admitting liability

(Sharecast News) - GSK announced on Thursday that it had reached a confidential settlement to effectively resolve the legal case over Zantac filed in a California state court.

Read more
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.